Home > Result Summaries: Compounds > naratriptan > Result Summary for S2W20006

Result Summary for S2W20006

Result Summary

Protocol ID:	S2W20006
Clinical Study ID:	S2W20006
Official Title:	A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria.
Phase:	Phase 4
Study Indications or Diseases:	Migraine Disorders and Premenstrual Syndrome
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Strevens H. Intermittent naratriptan can alleviate premenstrual irritability. Presented at the World Congress of Gyn & ObGyn Santiago, Chile, November 2003. Abstract: A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Savani, N, Loftus, J, Mansbach, H, and Scott, A 6th Headache Congress: European Headache Federation 6/26/2002 Istanbul, Turkey Abstract: Naratriptan in premenstrual dysphoria (pmd); a planned, double-blind, placebo-controlled, crossover study. Strevens, H, Samsioe, G, Wide-Swensson, D, and Sobenius, R 5th European Congress on Menopause 7/1/2000 Copenhagen, Denmark Abstract: Intermittent naratriptan 1 mg can alleviate premenstrual irritability in women with premenstrual dysphoria. Strevens, H, Samsioe, G, Wide-Swensson, D, Sobenius, R, and Loftus, J 44th Annual Scientific Meeting of the American Headache Society (AHS) 6/21/2002 Seatle, WA